Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement

NCT07184814 | Recruiting

• 1 other identifier: 2022-NHLHCRF-LX-01-01-02
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).

Conditions

Takayasu Arteritis With Pulmonary Artery Involvement; Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Outcome Measures

Primary Outcomes (1)

• All-cause death

  At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

Secondary Outcomes (3)

• Six-minute walk distance

  At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026

• WHO functional class

  At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

• N-terminal pro-brain natriuretic peptide level

  At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026

Other Outcomes (4)

• Mean pulmonary arterial pressure assessed by right heart catheterization

  At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

• Pulmonary vascular resistance assessed by right heart catheterization

  At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

• Cardiac output assessed by right heart catheterization

  At 3 months, 6 months, and annually thereafter following enrollment, until December 31, 2026.

Study Arms (1)

TAK-PAI group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

TAK patients hospitalized at the China-Japan Friendship Hospital, Beijing Anzhen Hospital and Beijing Chaoyang Hospital.

You may qualify if:

• Hospitalized between Jan 1, 2016 and Dec 31, 2026
• Diagnosed with TAK according to the modified Ishikawa criteria and/or 1990 American College of Rheumatology criteria and/or 2022 ACR/EULAR criteria
• Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography

You may not qualify if:

• Patients with PAI caused by non-TAK diseases such as other types of vasculitis, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis or chronic thromboembolic pulmonary hypertension

Sponsors & Collaborators

• China-Japan Friendship Hospital: lead

Study Sites (1)

China-Japan Friendship hospital

Beijing, Beijing Municipality, 100029, China

RECRUITING

Central Study Contacts

Wanmu Xie, Doctor

CONTACT

15611734410; xiewanmu@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director, Department of Integrative Pulmonary Medicine

Study Record Dates

• First Submitted: September 10, 2025
• First Posted: September 22, 2025
• Study Start: January 1, 2016
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: September 22, 2025

Record last verified: 2025-09

Locations

CN (1)